Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01950663 · ClinicalTrials.gov registry record · NA
RETeval Study for Diabetic Retinopathy
A NA study of Diabetic Retinopathy, sponsored by Inoveon Corporation.
- Completed
- Registry status
- NA
- Development phase
- 468
- Enrollment target
- 2
- Study locations
NCT01950663: Completed NA study of Diabetic Retinopathy, sponsored by Inoveon Corporation.
NCT01950663 is a NA study of Diabetic Retinopathy that has completed, run by Inoveon Corporation. The registered enrollment target is 468 participants, below the 1,668-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01950663, a NA study of Diabetic Retinopathy, has completed, sponsored by Inoveon Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 468 participants
- Enrollment target
- 2
- Study locations
Study Summary
RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy. The purpose of this study is to calibrate RETeval, and then measure its ability to detect vision threatening diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) 7-field, dilated, stereo, color fundus photography, read according to the ETDRS protocol, will be used as the gold standard.
Primary Outcome
Accuracy will be reported as count of participants with referral status correctly identified, sensitivity, and specificity, with ETDRS photography and reading as the gold standard.
Conditions Studied
Interventions
- DEVICE RETeval
Study Locations (2)
Georgia
- Atlanta VA Medical Center - Decatur
Oklahoma
- Oklahoma City VA Medical Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 468 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-04 |
| Phase | NA |
What the finished NCT01950663 record still lists
NCT01950663 is an interventional study that assigns participants to a tested intervention. The registered 468 participants enrollment target is mid-sized for trials with a published cap, below the 1,668-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 1 intervention - of which RETeval is the first listed.
NCT01950663 reports a single indexed study location in Georgia, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT01950663 about?
NCT01950663 is a clinical study titled "RETeval Study for Diabetic Retinopathy". RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy. The purpose of this study is to calibrate RETeval, and then measure its ability to detect vision threatening diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) 7-field, dilated, stereo,...
What is the current status of trial NCT01950663?
This trial is currently completed. It is a NA study. The enrollment target is 468 participants. The study started on 2013-09. Estimated completion is 2014-04.
What conditions does trial NCT01950663 study?
This clinical trial studies the following conditions: Diabetic Retinopathy.
What interventions are being tested in trial NCT01950663?
The interventions under investigation include: RETeval (DEVICE).
Who is sponsoring clinical trial NCT01950663?
This trial is sponsored by Inoveon Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01950663 being conducted?
This trial has 2 study locations across Georgia, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01950663's enrollment target sits among peer trials
468 18th of 57 higher than 40 of 57 other Diabetic Retinopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Retinopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
RECRUITING · NA
-
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
RECRUITING · NA
-
Clinical Applications of Advanced Ophthalmic Imaging
RECRUITING · NA
-
Implementation of Teleophthalmology in Urban Health Systems Study
ACTIVE NOT RECRUITING · NA
-
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03124303 · 468 participants
Interventions for Postoperative Delirium: Biomarker-3
- NCT03901924 · 468 participants · NA
Volume Support/Assist Control Mode Ventilation and Diaphragmatic Atrophy
- NCT04482309 · 468 participants · Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
- NCT05357170 · 468 participants
Microbiome Dysfunction in Surgical Intensive Care Unit Survivors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia